BioLife Solutions, Inc. confirmed that the Hart-Scott-Rodino antitrust waiting period for its acquisition by Repligen Corporation expired on September 3, 2026. According to the merger agreement, BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock per share of BioLife. A special shareholder meeting for voting on the merger agreement is scheduled for October 5, 2026. The acquisition is structured as two consecutive mergers.
Company Information
Company
Repligen Corporation
Location
Waltham, Massachusetts, United States
About
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
Don't miss Repligen Corporation's next move
Get an email the moment Repligen Corporation makes an acquisition, hires an exec, or expands, usually minutes after it happens.
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed
Frequently asked
Who acquired BioLife Solutions?
BioLife Solutions was acquired by Repligen Corporation, based in Waltham. The deal was reported on September 9, 2026. Repligen Corporation is publicly traded (RGEN) and operates in Manufacturing.
When did Repligen Corporation acquire BioLife Solutions?
Repligen Corporation's acquisition of BioLife Solutions was reported on September 9, 2026. BioLife Solutions, Inc. confirmed that the Hart-Scott-Rodino antitrust waiting period for its acquisition by Repligen Corporation expired on September 3, 2026. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does BioLife Solutions do?
BioLife Solutions, Inc. is a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. It is publicly traded (BLFS), operating in Biotechnology, and is based in Bothell.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
Waltham